Bardy Diagnostics Recognized by CIOReview as One of the 10 Most Promising Patient Monitoring Solution Providers of 2017

CHARLOTTE, N.C., Nov. 16, 2017 /PRNewswire/ -- Bardy Diagnostics, Inc., a leading provider of ambulatory cardiac technologies and custom data solutions, including the Carnation Ambulatory Monitor™ ("CAM™"), announced it has been recognized as one of the 10 Most Promising Patient Monitoring Solution Providers of 2017 by CIOReview Magazine, a notable technology publication aimed at C-level executives and decision-makers. Bardy Diagnostics was recognized for its innovative development and commercialization of CAM, the world's smallest and lightest P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

Bardy Diagnostics' CAM device was nominated and ultimately selected following CIOReview's annual comprehensive review of cutting edge technologies and solutions that shape the patient monitoring landscape. CIOReview's editorial team analyzed hundreds of companies that provide patient monitoring solutions and are at the forefront of solving patient and provider challenges. From that pool, 50 companies were shortlisted and reviewed by a distinguished panel comprised of CEOs, CIOs, VCs, and analysts, including the CIOReview editorial board, to further narrow the list to the final ten.

CAM distinguished itself from others in the nomination pool through its novel, state-of-the-art sensing architecture that incorporates ultra-low power, low-noise circuitry designed for the optimal detection and clear recording of the P-wave, the small amplitude ECG signal originating in the right atrium essential for accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention. Other monitoring technologies may not reliably detect or record the P-wave, resulting in inaccurate, vague, or missed diagnoses. In addition, CAM's discreet shape and lifestyle-enabling design increase patient compliance, resulting in uninterrupted data collection over longer periods of time when compared to traditional Holter monitors.

Commenting on the award, BDx Founder and Chief Executive Officer, Gust H. Bardy, MD, who in 2014 received the Pioneer in Cardiac Pacing and Electrophysiology Award, stated, "My passion is to bring innovative medical devices and products to the market for the benefit of the patient. All elements of the design and engineering processes we used in the development of the CAM were driven by the primary purpose of easy patient use and deployment to improve public health. I'm honored that CAM has captured those purposes and that it has been recognized as the innovative product that it is."

BDx Chief Operating Officer, Mark Handfelt, added, "CAM's innovative design permits us to offer our customers choices that aren't otherwise available to them with competitive technologies. For instance, the CAM recorder can be used for both short-term monitoring up to 48 hours and extended-term monitoring up to seven days. In addition, unlike competitive offerings, CAM users can elect to perform their own ECG analysis and report generation or have us provide the analysis and Carnation ECG Report to them. The CAM platform was designed with future innovation in mind as it will also permit us to add additional sensor types to meet the evolving needs of our customers and their patients. We look forward to bringing the benefits of this innovative monitor technology to clinicians and patients around the world."

The top 10 patient monitoring solution providers being recognized, along with a detailed feature on Bardy Diagnostics, can be found here in the November edition of CIOReview.

About Bardy Diagnostics
Bardy Diagnostics, Inc. ("BDx") develops and markets the Carnation Ambulatory Monitor, a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to be worn comfortably and discreetly by both men and women. Thoughtfully designed with the female anatomy in mind, CAM is placed on the center of the chest, directly over the heart for optimal ECG P-wave signal collection. Its state-of-the-art engineering enables optimal detection and clear recording of the P-waves.

Contact:  
Bardy Diagnostics, Inc.  
Jonathan Wu 
Director, Strategic Marketing
206-259-2876
[email protected]

www.bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links

http://www.bardydx.com